IRVINE, CA / ACCESSWIRE / September 28, 2017 / Khang & Khang LLP (the “Firm”) announces a securities class action lawsuit against Rayonier Advanced Materials Inc. (“Rayonier” or the “Company”) (NYSE: RYAM). Investors, who purchased or otherwise acquired Rayonier shares from October 29, 2014 through August 19, 2015, inclusive (the “Class Period”), are encouraged to contact the Firm in advance of the October 16, 2017 lead plaintiff motion deadline.

If you purchased Rayonier shares during the Class Period, please contact Joon M. Khang, Esq., of Khang & Khang LLP, 4000 Barranca Parkway, Suite 250, Irvine, CA 92604, by telephone at (949) 419-3834, or by e-mail at joon@khanglaw.com.

There has been no class certification in this case yet, and until certification occurs, you are not represented by an attorney. You may choose to take no action and remain a passive class member as well.

According to the Complaint, throughout the Class Period, Rayonier issued materially false and misleading statements, and/or failed to disclose adverse information. Specifically, despite the Company’s claims during the Class Period that in 2015 Rayonier “will be able to maintain or increase [its] share of volume at each of [its] top 10 customers,” since 2013, one of its top three customers, Eastman Chemical Company (“Eastman”), had been informing Rayonier of its competitors’ pricing and had requested that Rayonier respond to declines in market pricing. This led to a protracted dispute between Rayonier and Eastman over the “meet and release” provision of their agreement.

On August 18, 2015, the Company told investors that the Company filed an action against Eastman regarding its “chemical cellulose specialty products contract with Eastman.” On August 19, 2015, Rayonier issued a press release further explaining the dispute with Eastman, stating that the language in the contract at issue involved the “meet or release” provisions of the agreement, which allowed Eastman to obtain “third party offers that meet the requirements of the Supply Agreement for similar cellulose specialties products, and would require [Rayonier] to either meet such price or release the volume, thereby allowing Eastman to purchase the volume from the third party.” The release also stated that on August 12, 2017, Eastman filed an action against the Company regarding the same “meet or release” provisions in their contract. When this news was announced, shares of Rayonier fell in value materially, which caused investors harm according to the Complaint.

If you wish to learn more about this lawsuit, or if you have any questions concerning this notice or your rights, please contact Joon M. Khang, Esq., a prominent litigator for almost two decades, by telephone at (949) 419-3834, or by e-mail at joon@khanglaw.com.

This press release may constitute Attorney Advertising in some jurisdictions.

Contact:

Joon M. Khang, Esq.
Telephone: 949-419-3834
Facsimile: 949-225-4474
joon@khanglaw.com

SOURCE: Khang & Khang LLP

ReleaseID: 476605

IRVINE, CA / ACCESSWIRE / September 28, 2017 / Khang & Khang LLP (the “Firm”) announces a securities class action lawsuit against Blue Apron Holdings, Inc. (“Blue Apron” or the “Company”) (NYSE: APRN). Investors who purchased or otherwise acquired shares in connection with the June 29, 2017 initial public offering (the “IPO”), are encouraged to contact the Firm before October 16, 2017, the lead plaintiff motion deadline.

If you purchased Blue Apron shares pursuant and/or traceable to the IPO, please contact Joon M. Khang, Esq., of Khang & Khang LLP, 4000 Barranca Parkway, Suite 250, Irvine, CA 92604, by telephone at (949) 419-3834, or by e-mail at joon@khanglaw.com.

There has been no class certification in this case yet. Until certification occurs, you are not represented by an attorney. You may choose to take no action and remain a passive class member as well.

The Complaint alleges that the Registration Statement filed relating to the IPO failed to disclose that: Blue Apron decided to significantly reduce spending on advertising in Q2 2017, hurting sales and profit margins in future quarters; that the Company was experiencing difficulty with customer retention due to orders not arriving on time or with all expected ingredients; and that the Company was experiencing delayed orders in Q2 2017 related to its new factory in Linden, New Jersey. Since the IPO, Blue Apron’s stock price decreased materially, which caused investors harm according to the Complaint.

If you wish to learn more about this lawsuit, or if you have any questions regarding this notice or your rights, please contact Joon M. Khang, Esq., a prominent litigator for almost two decades, by telephone at (949) 419-3834, or by e-mail at joon@khanglaw.com.

This press release may constitute Attorney Advertising in certain jurisdictions.

Contact

Joon M. Khang, Esq.
Telephone: 949-419-3834
Facsimile: 949-225-4474
joon@khanglaw.com

SOURCE: Khang & Khang LLP

ReleaseID: 476604

IRVINE, CA / ACCESSWIRE / September 28, 2017 / Khang & Khang LLP (the “Firm”) announces a securities class action lawsuit against ZTO Express (Cayman) Inc. (“ZTO” or the “Company”) (NYSE: ZTO). Investors, who purchased or otherwise acquired ZTO shares in connection with its October 27, 2016 initial public offering (the “IPO”), are encouraged to contact the Firm before the October 16, 2017 lead plaintiff motion deadline.

If you purchased ZTO shares pursuant and/or traceable to the IPO, please contact Joon M. Khang, Esq., of Khang & Khang LLP, 4000 Barranca Parkway, Suite 250, Irvine, CA 92604, by telephone at (949) 419-3834, or by e-mail at joon@khanglaw.com.

There has been no class certification in this case yet. Until certification occurs, you are not represented by an attorney. You may choose to take no action and remain a passive class member as well.

According to the Complaint, the Registration Statement and Prospectus issued in connection with the IPO contained materially false and misleading information, and/or failed to disclose material information. At the time of the IPO, ZTO improperly inflated its stated profit margins by keeping certain low-margin segments of its business out of its financial statements. The Company failed to disclose that it used a system of “network partners” to handle lower-margin pickup and delivery services while maintaining ownership of core hub operations. ZTO was able to exaggerate its profit margins to investors by keeping the “network partners” businesses off its own books. Since the IPO, ZTO’s stock price fell materially, which caused investors harm according to the lawsuit.

If you wish to learn more about this lawsuit, or if you have questions concerning this notice or your rights, please contact Joon M. Khang, Esq., a prominent litigator for almost two decades, by telephone at (949) 419-3834, or by e-mail at joon@khanglaw.com.

This press release may be considered Attorney Advertising in certain jurisdictions.

Contact:

Joon M. Khang, Esq.
Telephone: 949-419-3834
Facsimile: 949-225-4474
joon@khanglaw.com

SOURCE: Khang & Khang LLP

ReleaseID: 476606

NEW YORK, NY / ACCESSWIRE / September 28, 2017 / The following statement is being issued by Levi & Korsinsky, LLP:

To: All persons or entities who purchased or otherwise acquired securities of Zillow Group, Inc. (“Zillow”) (NASDAQ: Z) between February 12, 2016 and August 8, 2017. You are hereby notified that a securities class action lawsuit has been commenced in the United States District Court for the Central District of California. To get more information, go to:

http://www.zlk.com/plsra-c/zillow-group-inc?wire=1

or contact Joseph E. Levi, Esq. either via email at jlevi@levikorsinsky.com or by telephone at (212) 363-7500, toll-free: (877) 363-5972. There is no cost or obligation to you.

The complaint alleges that, throughout the class period, Defendants issued materially false and/or misleading statements and/or failed to disclose that: (1) Zillow’s co-marketing program did not comply with the Real Estate Settlement Procedures Act; and (2) as a result, Zillow’s public statements were materially false and misleading at all relevant times.

If you suffered a loss in Zillow, you have until October 23, 2017 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff.

Levi & Korsinsky is a national firm with offices in New York, California, Connecticut, and Washington D.C. The firm’s attorneys have extensive expertise and experience representing investors in securities litigation, and have recovered hundreds of millions of dollars for aggrieved shareholders. Attorney advertising. Prior results do not guarantee similar outcomes.

CONTACT:

Levi & Korsinsky, LLP
Joseph E. Levi, Esq.
30 Broad Street – 24th Floor
New York, NY 10004
Tel: (212) 363-7500
Toll Free: (877) 363-5972
Fax: (212) 363-7171
www.zlk.com

SOURCE: Levi & Korsinsky, LLP

ReleaseID: 476582

NEW YORK, NY / ACCESSWIRE / September 28, 2017 / The following statement is being issued by Levi & Korsinsky, LLP:

To: All persons or entities who purchased or otherwise acquired American Depositary Shares of Teva Pharmaceutical Industries Ltd. (“Teva”) (NYSE: TEVA) between November 15, 2016 and August 2, 2017. You are hereby notified that a securities class action lawsuit has been commenced in the United States District Court for the Eastern District of Pennsylvania. To get more information, go to:

http://www.zlk.com/pslra-sbm/teva-pharmaceutical-industries-ltd?wire=1

or contact Joseph E. Levi, Esq. either via email at jlevi@levikorsinsky.com or by telephone at (212) 363-7500, toll-free: (877) 363-5972. There is no cost or obligation to you.

The complaint alleges that, throughout the Class Period, Defendants issued materially false and/or misleading statements and/or failed to disclose adverse information concerning the Company’s business and outlook. In particular, it is alleged that Teva failed to disclose and/or omitted the true negative impact of the acquisition and integration of Actavis Generics on the Company’s financial results and business prospects.

If you suffered a loss in Teva, you have until October 23, 2017 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff.

Levi & Korsinsky is a national firm with offices in New York, California, Connecticut, and Washington D.C. The firm’s attorneys have extensive expertise and experience representing investors in securities litigation, and have recovered hundreds of millions of dollars for aggrieved shareholders. Attorney advertising. Prior results do not guarantee similar outcomes.

CONTACT:

Levi & Korsinsky, LLP
Joseph E. Levi, Esq.
30 Broad Street – 24th Floor
New York, NY 10004
Tel: (212) 363-7500
Toll Free: (877) 363-5972
Fax: (212) 363-7171
www.zlk.com

SOURCE: Levi & Korsinsky, LLP

ReleaseID: 476583

IRVINE, CA / ACCESSWIRE / September 28, 2017 / Khang & Khang LLP (the “Firm”) announces a securities class action lawsuit against IntelliPharmaCeutics International Inc. (“IntelliPharmaCeutics” or the “Company”) (NASDAQ: IPCI). Investors, who purchased or otherwise acquired IntelliPharmaCeutics shares from January 14, 2016 through July 26, 2017, inclusive (the “Class Period”), are encouraged to contact the Firm by September 29, 2017, the lead plaintiff motion deadline.

If you purchased IntelliPharmaCeutics shares during the Class Period, please contact Joon M. Khang, Esq., of Khang & Khang LLP, 4000 Barranca Parkway, Suite 250, Irvine, CA 92604, by telephone at (949) 419-3834, or by e-mail at joon@khanglaw.com.

There has been no class certification in this case yet, and until certification occurs, you are not represented by an attorney. You may choose to take no action and remain a passive class member as well.

According to the Complaint, throughout the Class Period, IntelliPharmaCeutics made false and/or misleading statements and/or failed to disclose: that the Company failed to conduct a human abuse liability study to support its New Drug Application (“NDA”) for Rexista; that IntelliPharmaCeutics did not include abuse-deterrent studies conducted to suppose abuse-deterrent label claims related to abuse of the drug by various pathways; that the Company was not submitting enough data to support approval of the NDA; and that, as a result of the above, the Company’s statements about its business, operations, and prospects were false and misleading and/or lacked a reasonable basis at all relevant times. On July 24, 2017, scientists from the U.S. Food and Drug Administration (the “FDA”) expressed concerns that the Company failed to provide enough data about the abuse potential of Rexista. On July 26, 2017, IntelliPharmaCeutics announced that two advisory committees of the FDA voted 22 to 1 to oppose the Company’s NDA for Rexista, citing insufficient data about the abuse-deterrent properties of the drug as a motivating concern. Upon release of this news, the Company’s share price lowered materially, which caused investors harm according to the Complaint.

If you wish to learn more about this lawsuit, or if you have questions about this notice or your rights, please contact Joon M. Khang, Esq., a prominent litigator for nearly two decades, by telephone at (949) 419-3834, or via e-mail at joon@khanglaw.com.

This press release may be considered Attorney Advertising in certain jurisdictions.

Contact:

Joon M. Khang, Esq.
Telephone: 949-419-3834
Facsimile: 949-225-4474
joon@khanglaw.com

SOURCE: Khang & Khang LLP

ReleaseID: 476600

NEW YORK, NY / ACCESSWIRE / September 28, 2017 / The following statement is being issued by Levi & Korsinsky, LLP:

To: All persons or entities who purchased or otherwise acquired shares of Endo International plc (NASDAQ: ENDP) between November 30, 2012 and July 6, 2017. You are hereby notified that Levi & Korsinsky has commenced the class action Bier v. Endo International plc, et al. (Case No. 2:17-cv-03711-TJS) in the USDC for the Eastern District of Pennsylvania. Click here to view the complaint. To get more information, go to:

http://www.zlk.com/pslra-sbm/endo-international-plc?wire=1

or contact Joseph E. Levi, Esq. either via email at jlevi@levikorsinsky.com or by telephone at (212) 363-7500, toll-free: (877) 363-5972. There is no cost or obligation to you.

The complaint alleges that, throughout the Class Period, defendants made false and/or misleading statements and/or failed to disclose material information regarding the Company’s branded pharmaceutical Opana ER. In particular, the complaint alleges that the Company made materially false and/or misleading statements and/or failed to disclose that: (1) Reformulated Opana was not resistant to crushing; (2) Reformulated Opana was not abuse-deterrent and its use carried an inherent risk of abuse by grinding, snorting, or injecting; (3) Reformulated Opana was contributing to an opioid public health crisis; and (4) Endo would ultimately remove Reformulated Opana from the market.

If you suffered a loss in Endo, you have until October 17, 2017 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff.

Levi & Korsinsky is a national firm with offices in New York, California, Connecticut, and Washington D.C. The firm’s attorneys have extensive expertise and experience representing investors in securities litigation and have recovered hundreds of millions of dollars for aggrieved shareholders. Attorney advertising. Prior results do not guarantee similar outcomes.

CONTACT:

Levi & Korsinsky, LLP
Joseph E. Levi, Esq.
30 Broad Street – 24th Floor
New York, NY10004
Tel: (212) 363-7500
Toll-Free: (877) 363-5972
Fax: (212) 363-7171
www.zlk.com

SOURCE: Levi & Korsinsky, LLP

ReleaseID: 476581

VANCOUVER, BC / ACCESSWIRE / September 28, 2017 / Friday Night Inc. (“Friday Night”) (CNSX: TGIF) (FWB: 1QF) (OTC PINK: VPGDF) is pleased to announce the Land Use Application for its Special Use Permit has been accepted and filed and will be included on the November 8th agenda with the County Commissioners.

It is anticipated that the November 8th meeting will grant final approval and we can proceed to closing.

The updates to the building plans and engineering improvements are in process and the company expects to have a completed architectural rendering by October 12th, 2017.

About Friday Night Inc.

Friday Night Inc. is a Canadian public company, which owns and controls cannabis and hemp-based assets in Las Vegas Nevada. The company owns 91% of Alternative Medicine Association, LC (AMA), a licensed medical and adult-use cannabis cultivation and production facility that produces its own line of unique cannabis-based products and manufactures other third-party brands. Infused MFG, also a 91% owned subsidiary, produces hemp-based, CBD products, thoughtfully crafted of high quality organic botanical ingredients. Friday Night Inc. is focused on strengthening and expanding these operations within and outside of the state.

For further information, please contact:

Joe Bleackley, Corporate Communications
604-674-4756
Joe@FridayNightInc.com

Notice Regarding Forward-Looking Statements:

This news release contains forward-looking statements. The use of any of the words “anticipate,” “continue,” “estimate,” “expect,” “may,” “will,” “project,” “should,” “believe,” and similar expressions are intended to identify forward-looking statements. Although the Company believes that the expectations and assumptions on which the forward-looking statements are based are reasonable, undue reliance should not be placed on the forward-looking statements because the Company can give no assurance that they will prove to be correct. Since forward-looking statements address future events and conditions, by their very nature they involve inherent risks and uncertainties. These statements speak only as of the date of this news release. Actual results could differ materially from those currently anticipated due to a number of factors and risks including, inability to attract new customers in Nevada as a result of the license, the inability of the Company to take advantage of the license arrangement and various risk factors discussed in the Company’s disclosure documents, which can be found under the Company’s profile on www.sedar.com. Friday Night undertakes no obligation to update publicly or revise any forward-looking information, whether as a result of new information, future events or otherwise, except as required by law or the Canadian Securities Exchange.

SOURCE: Friday Night Inc.

ReleaseID: 476598

NEW YORK, NY / ACCESSWIRE / September 8, 2017 / The following statement is being issued by Levi & Korsinsky, LLP:

To: All persons or entities who purchased or otherwise acquired common stock of Blue Apron Holdings, Inc. (“Blue Apron”) (NYSE: APRN) pursuant and/or traceable to the Company’s Initial Public Offering on or around June 29, 2017. To get more information, go to:

http://www.zlk.com/pslra-sbm/blue-apron-holdings-inc

or contact Joseph E. Levi, Esq. either via email at jlevi@levikorsinsky.com or by telephone at (212) 363-7500, toll-free: (877) 363-5972. There is no cost or obligation to you.

The complaint filed in this class action alleges that Blue Apron violated the Securities Act of 1934 because the Registration Statement failed to disclose that: (1) rather than continue to significantly increase spending on advertising, Blue Apron had already decided to significantly reduce spending on advertising in Q2 2017, which would hurt sales and profit margins in future quarters; (2) Blue Apron was already experiencing adverse on-time in-full rates, meaning orders were not arriving on time or with all the ingredients needed, which was hurting customer retention; and (3) the Company had run into delays in Q2 2017 with its new factory in Linden, New Jersey.

If you suffered a loss in Blue Apron and would like to obtain additional information, contact Joseph E. Levi, Esq. either via email at jlevi@levikorsinsky.com or by telephone at (212) 363-7500, toll-free: (877) 363-5972, or visit http://www.zlk.com/pslra-sbm/blue-apron-holdings-inc.

Levi & Korsinsky is a national firm with offices in New York, California, Connecticut, and Washington D.C. The firm’s attorneys have extensive expertise and experience representing investors in securities litigation involving financial fraud and have recovered hundreds of millions of dollars for aggrieved shareholders. Attorney advertising. Prior results do not guarantee similar outcomes.

CONTACT:

Levi & Korsinsky, LLP
Joseph E. Levi, Esq.
30 Broad Street- 24th Floor
New York, NY10004
Tel: (212) 363-7500
Toll Free: (877) 363-5972
Fax: (212) 363-7171
www.zlk.com

SOURCE: Levi & Korsinsky, LLP

ReleaseID: 476580